BioCentury
ARTICLE | Clinical News

Ariad's brigatinib produces NSCLC responses

May 19, 2016 1:27 AM UTC

Brigatinib ( AP26113) from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) produced a 46-54% objective response rate (ORR) in an ongoing pivotal Phase II study to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, according to an abstract released ahead of next month's American Society of Clinical Oncology (ASCO) meeting. The compound is a dual inhibitor of ALK and EGFR.

Through Dec. 7, a high-dose regimen of brigatinib led to 49 confirmed and 10 unconfirmed responses, including five complete responses, among 110 patients previously treated with Xalkori crizotinib from Pfizer Inc. (NYSE:PFE). A lower dose led to 39 confirmed and 12 unconfirmed responses, including one complete response, among 112 patients. The study's primary endpoint is confirmed ORR. ...